Company Description
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.
The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy.
The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy.
It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 423 |
| CEO | Helen Torley |
Contact Details
Address: 12390 El Camino Real San Diego, California 92130 United States | |
| Phone | 858 794 8889 |
| Website | halozyme.com |
Stock Details
| Ticker Symbol | HALO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001159036 |
| CUSIP Number | 40637H109 |
| ISIN Number | US40637H1095 |
| Employer ID | 88-0488686 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. | President, Chief Executive Officer and Director |
| Nicole LaBrosse CPA | Senior Vice President and Chief Financial Officer |
| Mark Snyder Esq. | Senior Vice President, General Counsel, Chief Compliance Officer and nd Secretary |
| Cortney Caudill M.B.A. | Senior Vice President and Chief Operating Officer |
| Tram Bui | Head of Investor Relations and Corporate Communications |
| Dr. Christopher Wahl M.B.A., M.D. | Chief Scientific Officer |
| Dr. Charles P. Theuer M.D., Ph.D. | Chief Medical Officer |
| Paul Spence | Chief Commercial Officer |
| Rhys de Callier | Chief Strategy Officer |
| Chase Coffman Ph.D. | President of Hypercon |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 17, 2026 | 10-K | Annual Report |
| Feb 17, 2026 | 8-K | Current Report |
| Feb 3, 2026 | 144 | Filing |
| Jan 28, 2026 | 8-K | Current Report |
| Jan 5, 2026 | 144 | Filing |
| Dec 9, 2025 | 8-K | Current Report |
| Dec 8, 2025 | 8-K | Current Report |
| Nov 24, 2025 | 8-K | Current Report |
| Nov 18, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 12, 2025 | 8-K | Current Report |